Equities research analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce ($0.02) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Antares Pharma’s earnings, with estimates ranging from ($0.04) to ($0.01). Antares Pharma posted earnings per share of ($0.01) in the same quarter last year, which suggests a negative year-over-year growth rate of 100%. The company is expected to report its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.10) to ($0.05). For the next financial year, analysts forecast that the business will report earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.03. The firm had revenue of $28.43 million during the quarter, compared to the consensus estimate of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.
ATRS stock traded down $0.12 during mid-day trading on Thursday, reaching $3.12. The company had a trading volume of 663,380 shares, compared to its average volume of 1,024,493. The company has a debt-to-equity ratio of 1.01, a current ratio of 3.46 and a quick ratio of 2.87. The stock has a 50 day simple moving average of $3.21 and a two-hundred day simple moving average of $3.10. The company has a market capitalization of $508.75 million, a price-to-earnings ratio of -78.00 and a beta of 0.95. Antares Pharma has a 52 week low of $2.53 and a 52 week high of $3.96.
Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its holdings in Antares Pharma by 54,541.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 30,053 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 29,998 shares during the last quarter. Searle & CO. acquired a new stake in Antares Pharma during the 1st quarter worth approximately $61,000. Perkins Capital Management Inc. lifted its holdings in Antares Pharma by 7.8% during the 1st quarter. Perkins Capital Management Inc. now owns 441,000 shares of the specialty pharmaceutical company’s stock worth $1,336,000 after purchasing an additional 32,000 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Antares Pharma during the 1st quarter worth approximately $123,000. Finally, Enterprise Bank & Trust Co acquired a new stake in Antares Pharma during the 1st quarter worth approximately $45,000. Institutional investors own 43.10% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Recommended Story: Trading Stocks – What are percentage gainers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.